tirzepatide uptodate (LY3298176) is a Dual GIP and GLP-1 Receptor Agonist for Type 2 Diabetes Research Tirzepatide (For R&D) DMF 039791
Description
While mild appetite fluctuations during tirzepatide therapy may not require immediate intervention, certain situations warrant prompt communication with your healthcare provider to ensure treatment safety and efficacy
They are prepared by licensed pharmacies using active ingredients under the direction of a prescribing clinician
The peptide appears to shift the body's fuel preference toward stored fat, which explains some of its weight management effects
Overall, triggering the activation of BAT or inducing the browning of WAT offers a highly effective approach to obesity treatment [16,19]
